Uncategorized

Know Before You File: Using Patent Landscape Analysis to Drive Go/No-Go Decisions in Generic and Biosimilar Drug Development

Most teams don’t lose on science—they lose on timing.
In generic and biosimilar development, the “go/no-go” decision is often framed as a technical question: Can we make it? Can we prove it? Can we hit the right endpoints?
But the real inflection p…

Know Before You File: Using Patent Landscape Analysis to Drive Go/No-Go Decisions in Generic and Biosimilar Drug Development Read Post »

Uncategorized

Own the Clock: How Pharma Companies Extract Maximum Value from Patent Term Extensions and Secondary Patents

Pharma doesn’t just “own” a drug patent—it often extends control over time.
That’s the core tension behind the industry’s playbook for maximizing value from patent term extensions and secondary patents. In a world where blockbuster revenue is measured …

Own the Clock: How Pharma Companies Extract Maximum Value from Patent Term Extensions and Secondary Patents Read Post »

Biotechblog
Scroll to Top